Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
To determine if Exparel (Liposomal Bupivacaine, an FDA approved drug) use in ultrasound
guided Transversus Abdominis Plane (TAP) blocks may reduce opioid requirement use
postoperatively, reduce pain scores postoperatively, reduce incidence of nausea in the postop
period, and decrease length of hospital stay